Latest news with #ZevraTherapeutics
Yahoo
27-05-2025
- Business
- Yahoo
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT
In a report released on May 27, Jason Butler from Citizens JMP reiterated a Buy rating on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) with a price target of $19.00. Its fiscal Q1 2025 results, reported on May 15, showed positive operations, with net revenue reaching $20.4 million, driven by product net revenue of $17.2 million. The company beat earnings expectations with a reported EPS of $-0.06, which exceeded the expected $-0.21. A scientist in a lab coat with a microscope magnifying a sample of a rare disease therapy. Zevra Therapeutics, Inc. (NASDAQ:ZVRA) announced the closing of the sale of its Pediatric Rare Disease Priority Review Voucher (PRV) on April 7 to an undisclosed buyer, supporting the optimistic sentiment for the stock with gross proceeds of $150 million. The proceeds position the company to strengthen its balance sheet and support development programs and commercial launches. Zevra Therapeutics, Inc. (NASDAQ:ZVRA) is a commercial-stage company that develops therapies for rare diseases with limited or no treatment options. Its product portfolio focuses on rare neurological and sleep conditions, including Idiopathic Hypersomnia, Urea Cycle Disorders, and Niemann-Pick disease type C. While we acknowledge the potential of ZVRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZVRA and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
13-05-2025
- Business
- Washington Post
Zevra Therapeutics: Q1 Earnings Snapshot
CELEBRATION, Fla. — CELEBRATION, Fla. — Zevra Therapeutics, Inc. (ZVRA) on Tuesday reported a loss of $3.1 million in its first quarter. The Celebration, Florida-based company said it had a loss of 6 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.
Yahoo
01-05-2025
- Business
- Yahoo
Zevra Therapeutics to Participate in the Citizens Life Science Conference
CELEBRATION, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage rare disease therapeutics company, today announced that members of Zevra's executive leadership team will participate in a fireside chat at the Citizens Life Science Conference in New York, NY, on Wednesday, May 7, 2025, at 11:30 a.m. ET. Additionally, management will be available for one-on-one meetings with registered attendees at each conference. The live webcasts will be accessible via 'Events & Presentations' on the Investor Relations section of Zevra's website at About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit or follow us on X and LinkedIn. Caution Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra's participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended Dec. 31, 2024, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@ Sign in to access your portfolio
Yahoo
07-04-2025
- Business
- Yahoo
Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
CELEBRATION, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $150 million. 'We have reached another key milestone with the closing on the sale of our PRV, which we received following the successful approval of MIPLYFFATM (arimoclomol) from the U.S. Food and Drug Administration (FDA),' said LaDuane Clifton, Zevra's Chief Financial Officer. 'The $150 million in gross proceeds is non-dilutive capital that further enhances our financial flexibility to support our strategic priorities, which includes executing on the commercial launches of MIPLYFFA and OLPRUVA®, supporting our ongoing Phase 3 trial for celiprolol, and augmenting our solid balance sheet to support future investments that are in alignment with our strategic plan.' Zevra was granted the PRV in September 2024 by the FDA, in connection with the FDA's approval of MIPLYFFA, the first U.S. approved treatment for the ultra-rare neurodegenerative disease, Niemann-Pick type C. In addition, the Company reported that available unaudited cash, cash equivalents and investments as of Mar. 31, 2025, were $68.7 million. Combined with the cash proceeds of $148.3 million, net of fees, from the sale of the PRV after the end of the quarter, cash, cash equivalents and investments would be $217.0 million. About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit or follow us on X and LinkedIn. Financial Disclosure Advisory The cash, cash equivalents and investments information provided in this press release is based on preliminary unaudited information and management estimates for the quarter ended March 31, 2025, is not a comprehensive statement of the Company's financial results as of and for the fiscal quarter ended March 31, 2025 or any other period, and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted a review of and does not express an opinion or any other form of assurance with respect to this preliminary estimate. Cautionary Note Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the potential benefits of any of our products or product candidates for any specific disease or at any dosage; the progress of our clinical trials, our strategic and product development objectives; the benefits of the transaction and its impact on the Company's balance sheet or strategic goals; our financial position, including our cash, cash equivalents and investments and available resources; and the timing of any of the foregoing. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, assumptions, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner+1 (732) 754-2545nochsner@ Media Contact Russo PartnersDavid Schull+1 (858) in to access your portfolio
Yahoo
23-03-2025
- Business
- Yahoo
Zevra Therapeutics Independent Director Acquires 33% More Stock
Whilst it may not be a huge deal, we thought it was good to see that the Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Independent Director, John Bode, recently bought US$80k worth of stock, for US$7.96 per share. While we're hesitant to get too excited about a purchase of that size, we do note it increased their holding by a solid 33%. Notably, that recent purchase by John Bode is the biggest insider purchase of Zevra Therapeutics shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$8.01. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. The good news for Zevra Therapeutics share holders is that insiders were buying at near the current price. Zevra Therapeutics insiders may have bought shares in the last year, but they didn't sell any. They paid about US$6.89 on average. To my mind it is good that insiders have invested their own money in the company. However, you should keep in mind that they bought when the share price was meaningfully below today's levels. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! Check out our latest analysis for Zevra Therapeutics There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them). Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 6.6% of Zevra Therapeutics shares, worth about US$29m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. It's certainly positive to see the recent insider purchase. We also take confidence from the longer term picture of insider transactions. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Zevra Therapeutics insiders are well aligned, and that they may think the share price is too low. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Zevra Therapeutics. Our analysis shows 2 warning signs for Zevra Therapeutics (1 is concerning!) and we strongly recommend you look at them before investing. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
